Antimicrobial susceptibility to last-resort antibiotics in carbapenemase-producing bacteria from Ukrainian patients
- PMID: 39315812
- PMCID: PMC11537089
- DOI: 10.1128/spectrum.01142-24
Antimicrobial susceptibility to last-resort antibiotics in carbapenemase-producing bacteria from Ukrainian patients
Abstract
Since March 2022, an increase was observed in multidrug-resistant microorganisms (MDRO), associated with the hospital transfer of Ukrainian patients. The goal was to collect phenotypic susceptibility data and assess clinical implications. Carbapenemase-producing Enterobacterales (CPE, n = 96), Pseudomonas aeruginosa (CPPA, n = 20), and carbapenem-resistant Acinetobacter baumannii-calcoaceticus (CRAB, n = 6) from Ukrainian patients were obtained from March to December 2022 from the Dutch MDRO surveillance. Antimicrobial susceptibility testing was performed using broth microdilution (BMD) when available, fosfomycin agar dilution, disk diffusion (DD) for cefiderocol, and diverse gradient strips. All isolates were sequenced with Illumina next-generation sequencing. For meropenem, aminoglycosides, ceftazidime-avibactam, ceftolozane-tazobactam, and imipenem-relebactam, susceptibility rates were low (0%-30%), due to the high number of blaNDM-positive isolates (79/122; 65%). For cefiderocol, results depended on reading with or without microcolonies, applying EUCAST or CLSI breakpoints, and whether DD or BMD was used; e.g., for Klebsiella pneumoniae, 30%-97% were susceptible. For colistin, 103/111 (93%) non-intrinsically resistant CPE/CPPA/CRAB isolates were susceptible. For most CPE, a low minimal inhibitory concentration (MIC) of <0.5 mg/L was measured for tigecycline and ceftazidime-avibactam-aztreonam. For CPPA, cefiderocol tested susceptible in 65%-100% of isolates. For CRAB, ampicillin-sulbactam MICs were ≥128 mg/L; for sulbactam-durlobactam, 1-2 mg/L. Admission in a Ukrainian hospital in the last year was a risk factor for MDRO, and majority were screening isolates (79%). There is extensive phenotypic resistance to last-resort antibiotics in MDRO from Ukrainian patients. Interpretation of cefiderocol susceptibility results depends on several variables. When treating patients recently admitted in Ukraine, suspected for Gram-negative bacterial infection, this should be taken into consideration.
Importance: Since March 2022, multidrug-resistant microorganisms associated with Ukrainian patients have been detected in national surveillance systems of several European countries. We studied the phenotypic antimicrobial susceptibility to last-resort antibiotics of multidrug-resistant microorganisms from Ukrainian patients in the Netherlands and assessed clinical implications. Our research revealed that there was extensive phenotypic resistance to last-resort antibiotics. Healthcare professionals should be aware of multidrug-resistant microorganisms when treating patients recently admitted in Ukraine, suspected for Gram-negative bacterial infection.
Keywords: Acinetobacter baumannii; Pseudomonas aeruginosa; Ukraine; War; antimicrobial susceptibility testing; carbapenemase-producing Enterobacterales; cefiderocol; ceftazidime–avibactam; ceftolozane–tazobactam; imipenem–relebactam; multidrug-resistant microorganisms.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


References
-
- Zwittink RD, Wielders CC, Notermans DW, Verkaik NJ, Schoffelen AF, Witteveen S, Ganesh VA, de Haan A, Bos J, Bakker J, Schneeberger-van der Linden C, Kuijper EJ, de Greeff SC, Hendrickx AP, Dutch CPE and MRSA Surveillance Study Groups . 2022. Multidrug-resistant organisms in patients from Ukraine in the Netherlands, March to August 2022. Euro Surveill 27:50. doi:10.2807/1560-7917.ES.2022.27.50.2200896 - DOI - PMC - PubMed
-
- Sandfort M, Hans JB, Fischer MA, Reichert F, Cremanns M, Eisfeld J, Pfeifer Y, Heck A, Eckmanns T, Werner G, Gatermann S, Haller S, Pfennigwerth N. 2022. Increase in NDM-1 and NDM-1/OXA-48-producing Klebsiella pneumoniae in Germany associated with the war in Ukraine, 2022. Euro Surveill 27:50. doi:10.2807/1560-7917.ES.2022.27.50.2200926 - DOI - PMC - PubMed
-
- Ljungquist O, Nazarchuk O, Kahlmeter G, Andrews V, Koithan T, Wasserstrom L, Dmytriiev D, Fomina N, Bebyk V, Matuschek E, Riesbeck K. 2023. Highly multidrug-resistant Gram-negative bacterial infections in war victims in Ukraine, 2022. Lancet Infect Dis 23:784–786. doi:10.1016/S1473-3099(23)00291-8 - DOI - PubMed
-
- Wielders CCH, Schouls LM, Woudt SHS, Notermans DW, Hendrickx APA, Bakker J, Kuijper EJ, Schoffelen AF, de Greeff SC, Infectious Diseases Surveillance Information System-Antimicrobial Resistance (ISIS-AR) Study Group, Dutch CPE Surveillance Study Group . 2022. Epidemiology of carbapenem-resistant and carbapenemase-producing Enterobacterales in the Netherlands 2017–2019. Antimicrob Resist Infect Control 11:57. doi:10.1186/s13756-022-01097-9 - DOI - PMC - PubMed
-
- Pirzadian J, Persoon MC, Severin JA, Klaassen CHW, de Greeff SC, Mennen MG, Schoffelen AF, Wielders CCH, Witteveen S, van Santen-Verheuvel M, Schouls LM, Vos MC, Dutch CPE surveillance Study Group . 2021. National surveillance pilot study unveils a multicenter, clonal outbreak of VIM-2-producing Pseudomonas aeruginosa ST111 in the Netherlands between 2015 and 2017. Sci Rep 11:21015. doi:10.1038/s41598-021-00205-w - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous